STOCK TITAN

[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
-
-
-
-
-
Positive
  • None.
Negative
  • None.
-
-
-
-
-
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-41923

EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968 

(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

 

 


DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit  
  
99.1 Press Release dated July 8, 2025


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  EUPRAXIA PHARMACEUTICALS INC.
   
  
Date: July 8, 2025 By: /s/ Alex Rothwell                     
  Name: Alex Rothwell
  Title: Chief Financial Officer
  
Eupraxia Pharmac

NASDAQ:EPRX

EPRX Rankings

EPRX Latest News

EPRX Stock Data

209.36M
28.97M
22.56%
13.09%
0.44%
Biotechnology
Healthcare
Link
Canada
Victoria